Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Oral Contraceptives in Binge Eating
NCT04278755Phase 2Terminated
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of drospirenone in binge eating disorder (BED) and bulimia nervosa (BN), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Weekly Average Binge-eating Frequency at 12 weeks, Binge Eating Sum Score at 12 weeks and 4 more. Started Sep 2020; status: terminated.
02
Drugs
drospirenone
03
Conditions
binge eating disorder (BED)bulimia nervosa (BN)
Beyond the preview
Go deeper on NCT04278755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278755.